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Abstract
Lysyl oxidase propeptide (LOX-PP) ectopic overexpression inhibits the growth of cancer xenografts. Here the ability and
mode of action of purified recombinant LOX-PP (rLOX-PP) protein to inhibit the growth of pre-existing xenografts was
determined. Experimental approaches employed were direct intratumoral injection (i.t.) of rLOX-PP protein into murine
breast cancer NF639 xenografts, and application of a slow release formulation of rLOX-PP implanted adjacent to tumors in
NCR nu/nu mice (n=10). Tumors were monitored for growth, and after sacrifice were subjected to immunohistochemical
and Western blot analyses for several markers of proliferation, apoptosis, and for rLOX-PP itself. Direct i.t. injection of rLOX-
PP significantly reduced tumor volume on days 20, 22 and 25 and tumor weight at harvest on day 25 by 30% compared to
control. Implantation of beads preloaded with 35 micrograms rLOX-PP (n=10) in vivo reduced tumor volume and weight at
sacrifice when compared to empty beads (p,0.05). A 30% reduction of tumor volume on days 22 and 25 (p,0.05) and final
tumor weight on day 25 (p,0.05) were observed with a reduced tumor growth rate of 60% after implantation. rLOX-PP
significantly reduced the expression of proliferation markers and Erk1/2 MAP kinase activation, while prominent increases in
apoptosis markers were observed. rLOX-PP was detected by immunohistochemistry in harvested rLOX-PP tumors, but not in
controls. Data provide pre-clinical findings that support proof of principle for the therapeutic anti-cancer potential of rLOX-
PP protein formulations.
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Introduction
Lysyl oxidase (LOX) is a copper-dependent, extracellular matrix
enzyme required for the normal biosynthesis of mature and
functional collagens and elastin [1]. LOX is made as a 50 kDa
proenzyme and processed extracellularly to a ,30 kDa mature
LOX enzyme and the ,18 kDa propeptide (LOX-PP) by
procollagen C-proteinases [2], encoded by the bone morphogenetic
protein-1 and the tolloid-like-1 and -2 genes [3,4]. The LOX gene has
been shown to have ‘‘RAS rescission’’ activity, and this tumor
suppressor activity of the LOX gene has been mapped to its
propeptide region [5]. Natural and recombinant LOX-PP has N-
and O-linked carbohydrates and a very high isoelectric point. The
characterization of purified recombinant LOX-PP (rLOX-PP)
showed that it is a highly disordered protein and is, therefore,
predicted to have multiple binding partners and more than one
mechanism of action [6].
LOX enzyme activity has been reported to promote tumor
invasiveness [7,8]. LOX enzyme and LOX-PP are derived from
the same mRNA, as summarized above. Interestingly, estrogen
receptor positive breast cancer tumors are less invasive than
estrogen receptor negative tumors, and express lower levels of
LOX mRNA [9]. Taken together, data suggest a model in which
abnormally low levels of LOX-PP may permit tumor growth,
whereas abnormally high LOX enzyme may promote tumor
invasion. Our interest here is to investigate the potential of rLOX-
PP protein to inhibit tumor growth in vivo.
LOX-PP inhibits RAS-dependent transformation of NIH 3T3
fibroblasts assessed by inhibition of cell proliferation, growth in soft
agar and Akt- and Erk1/2 dependent induction of NF-kappaB in
vitro [5]. In breast cancer, LOX-PP was shown to reverse the
invasive phenotype of Her2/neu driven breast cancer cells, inhibit
epithelial to mesenchymal transition, and inhibit migration and
branching colony formation. Retrovirus mediated ectopic overex-
pression of LOX-PP in NF639 cells suppresses xenograft tumor
formation in nude mice [10]. In human lung and pancreatic
cancer cells, LOX-PP reduces migration, Erk1/2 and Akt
signaling, and growth in soft agar and represses BCL-2 levels
[11]. Doxorubicin is a chemotherapeutic drug which induces
apoptosis in cancer cells. Pre-treatment of pancreatic and breast
cancer cells with rLOX-PP sensitizes the cancer cells to
doxorubicin-induced apoptosis in vitro, whereas LOX-PP alone
did not appear to induce apoptosis [12]. LOX-PP inhibits different
signaling pathways. LOX-PP reduces tyrosine phosphorylated
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cas protein, and reduces haptotaxis of NF639,
MDA-MB-231 and Hs578T breast cancer cells and thus
attenuates fibronectin mediated integrin signaling [13]. rLOX-
PP inhibits FGF-2 induced DNA synthesis, Erk1/2 and Akt
signaling and FRS2alpha activation in DU145 prostate cancer
cells and in the phenotypically normal MC3T3-E1 osteoblastic cell
line [14,15]. Interestingly, the single nucleotide Arg158G
polymorphism in a carboxy-terminal conserved region results in
loss of some of the LOX-PP tumor suppressor properties [9], while
some intracellular mechanisms of action depend on the amino-
terminal end [16]. Taken together, the various studies have shown
that LOX-PP has a tumor suppressor property, inhibits RAS,
FGF-2, and FAK signaling, and that different conserved regions
mediate its activity.
These studies strongly suggest that LOX-PP could have
potential as a cancer therapeutic. The major goal of this study
was to evaluate the ability of rLOX-PP protein to inhibit or
reverse the growth of pre-existing breast cancer xenografts, first by
direct intratumoral injection (i.t.); and second, by a slow release
formulation in order to establish proof of principle that rLOX-PP
protein formulations can have the potential as an in vivo cancer
therapeutic. In order to gain insights into the mode of action of
rLOX-PP protein in vivo, the effect on breast cancer xenograft cell
proliferation and apoptosis was determined. Moreover, data
suggest that LOX-PP protein persists in tumors particularly when
administered by a slow release formulation in vivo. These findings
support the notion that formulations of rLOX-PP may ultimately
prove to have therapeutic utility in cancer therapy.
Materials and Methods
Cell line and Mouse xenograft model
The mouse mammary tumor virus (MMTV)-Her-2/neu NF639
cell line kindly provided by Dr. P. Leder [17] was grown in
DMEM supplemented with 10% FBS. All experiments were
performed as approved by Boston University Medical Center
IACUC. In both experiments, the single cell suspensions in
DMEM were prepared. NF639 cells (4610
6 cells) were injected
subcutaneously into the midline dorsa (n=10/condition) of NCR
nu/nu mice (Charles River Laboratories), and tumors allowed to
grow to 100 mm
3. Caliper measurements were made at intervals
to monitor the volume of all tumors.
Intratumoral injection
Purified rLOX-PP (10 micrograms) expressed by HEK293 cells
[6] in PBS or PBS alone (vehicle) was injected once per day i.t. for
5 days starting on day 17 when the average tumor volume was
100 mm
3. Mice were monitored and maintained until day 21 at
which time the PBS injected control tumors reached 1000 mm
3.
rLOX-PP slow release formulation in alginate beads
Alginate beads containing rLOX-PP and empty control beads
were made according to a standard protocol [18] as follows. rLOX-
PP (1 mg/ml) [6] and 18 mg/ml sodium alginate were mixed at a
ratio of 1:2 and the slurry was passed drop-wise through a 21 gauge
needle into a solution of CaCl2 (1.5% w/v) with gentle mixing.
Mixing was continued for five minutes, and then beads were
allowed to settle for 10 minutes. Beads were washed three times in
sterile water and storedin150 mMNaCl, 1 mMCaCl2 at 4uC until
used. LOX-PP incorporation within the beads was calculated based
on a 70% incorporation efficiency measured previously with other
growth factors of similar size and molecular properties [19,20].
Empty beads were made without addition of rLOX-PP. Bead size
was measured with a digital caliper (Fisher Scientific) and an
average diameter of 1.5060.12 mm (n=20) was noted. Animal
studies were conducted with a single preparation of beads to avoid
batch to batch variability.
rLOX-PP in vitro release kinetics from LOX-PP/alginate
beads
rLOX-PP release kinetics from calcium alginate beads were
determined in vitro over a 14 day period. Three beads containing
1 mg rLOX-PP each were incubated in 1 ml release buffer
(150 mM NaCl, 1 mM CaCl2, 0.05% gelatin) with n=4 at 37uC
with constant shaking. The supernatant was collected on days 0, 1,
3, 7, 10 and 14. At each time point, the entire supernatant was
removed and replenished with 1 ml fresh release buffer. Samples
were boiled in 1X SDS PAGE sample buffer and aliquots were
subjected to Western blot analysis, and compared to standard
curves of rLOX-PP determined from the same blots after
densitometric analyses and linear regression with the aid of a
Versadoc densitometer and Quantity One software (BioRad).
Total cumulative rLOX-PP released was then calculated.
In vivo implantation of rLOX-PP alginate beads
NF639 cells (4610
6) were injected once in the dorsum of each
mouse and tumors were allowed to grow to 300 mm
3 (n=10/
group). Then, 35 micrograms rLOX-PP in beads, or empty
alginate beads (n=10) were surgically implanted adjacent to each
experimental and control tumor, respectively, on lateral sides of
tumor borders and subsequently sutured with vicryl 4.0 biode-
gradable sutures. Tumor volumes were monitored by caliper
measurements made at regular intervals, and tumor weights were
determined at sacrifice.
Histology and immunohistochemistry
All tumors were harvested at sacrifice and then fixed in 4%
paraformaldehyde for three hours, and then placed in 30%
sucrose overnight at 4uC. Frozen sections were made and
subjected to immunohistochemistry and quantitative histomor-
phometric analyses [21]. Four tumors, 3 to 4 sections per tumor,
were used for immunohistochemistry staining analysis for the
proliferation marker, Ki-67 (Abcam Inc.; ab15580), phospho-
histone H3 (Millipore; 06-570), the apoptosis marker active
caspase 3 (Trevigen, Gaithersburg, MD, USA; 2305-PC-020),
and LOX-PP itself (Novus, NB110-41568). Apoptosis was further
evaluated using a kit for the terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) assay according to the
manufacturer’s instructions (Trevigen, Gaithersburg, MD, USA;
4815-30-K) [22]. Quantitation of micrographs was performed
independently by two experienced researches MB and SSS) in a
blinded fashion according to previous protocols performed by this
laboratory [21,23,24]. Five independent 0.09 mm
2 grids on three
sections per animal were measured; a minimum of three mice per
group was analyzed as indicated for each assay.
Western blotting
Snap frozen tumors were ground to a fine powder in liquid
nitrogen and then extracted into SDS PAGE sample buffer
(0.1 mM Tris-HCl, 4% SDS, 10% glycerol, 5% b-mercaptoeth-
anol). Protein concentrations were determined using Nano Orange
assay kits (Molecular Probes, Eugene, OR, USA). Approximately
10 micrograms of protein from 3 tumors per experimental group
were then subjected to 10% SDS PAGE and Western blotting with
primary antibodies for mitosis marker phospho-histone H3
(Millipore, Billerica, MA, USA; 06-570), the downstream targets
of Ras signaling phospho-Erk1/2, total Erk1/2, and normalization
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9101S, 9102S and 4970L, respectively). Anti-rabbit secondary
antibodies were purchased from Cell Signaling Technology
(Danvers, MA, USA; 7074S). The quantifications were performed
by a digital densitometry system and Quantity One software
(Versadoc; BioRad, Eugene, OR, USA).
Statistics
Analyses of all experiments were done using two way ANOVA
with Bonferroni post-hoc analysis or Student’s t-test (GraphPad
Prism 5 software). Data are presented as means +/2 SD.
Results
Intratumoral injection of rLOX-PP inhibits pre-existing
breast cancer xenografts
Earlier studies have shown that the ectopic expression of LOX-
PP inhibits breast and pancreatic cancer xenograft growth, and
proliferation of prostate cancer cells in vitro [10,12,14]. To evaluate
whether rLOX-PP protein can inhibit the growth of preexisting
tumors in vivo, we used a breast cancer xenograft model. NF639
breast cancer cells (4610
6 cells) were injected subcutaneously into
the dorsal region of nude mice and tumors allowed to grow to a
volumeof100 mm
3 (day17).Micewerethendivided randomly into
two groups with 10 mice each. Mice were injected once per day
beginning on day 17 for five consecutive days with 10 micrograms
rLOX-PP or vehicle (PBS) in a volume of 100 microliters. Caliper
measurementswerecontinuedthroughday25atwhich timetumors
injected with vehicle (controls) reached a volume of 1000 mm
3.
Data inFigure 1Ashow that on day25 the average tumorvolumein
the rLOX-PP i.t. injection group was 7436101 mm
3 compared
with PBS control (10436199 mm
3) showing significantly inhibited
tumor growth in LOX-PP treated tumors (p#0.05). The growth
rate was plotted from the tumor volume measurements beginning
on day 18. The growth rate in the vehicle group was 125 mm
3 per
day compared to 85 mm
3 per day in rLOX-PP treated tumors
(Figure 1B). Consistent with the above findings, the tumor weights
determined at sacrifice were smaller in the rLOX-PP injected group
(Figure 1C) but not significantly different from control (p=0.41).
Thus, the data show that i.t. injection of rLOX-PP significantly
inhibits the tumor volume growth by 28% on day 25 and growth
rate by 32% after day 18 compared to PBS, and a trend toward
diminished tumor weight was found.
Sustained release of rLOX-PP
To evaluate whether rLOX-PP could be stabilized for slow and
sustained release and provide enhanced stability and possibly
increased biological activity in vivo, we incorporated rLOX-PP
into alginate beads. Alginate is a naturally occurring aquatic plant
polysaccharide polymer and alginate beads have been used
previously for successful slow release of FGF-2 and other proteins
with high isoelectric points without loss of biological activity
[18,25]. rLOX-PP is also a highly basic protein with a high
isoelectric point [6]. In order to determine whether rLOX-PP can
be released from alginate beads in a time-dependent manner, in
vitro release kinetics were determined as outlined in Materials and
Methods. Data in Figure 2 indicate that rLOX-PP is released
Figure 1. Injection of rLOX-PP inhibits NF639 xenograft growth in mice. (A) Subcutaneous xenografts of NF639 breast cancer cells were
injected once daily with 10 micrograms rLOX-PP for 5 days beginning on day 17 (arrows). Tumor volumes were monitored by caliper measurements
(n=10; *, p,0.05); (B) The tumor growth rates were determined from measurements made beginning on day 18 and were derived from linear
regression analyses of the data. (C) Tumor weights at sacrifice on day 25 (p=0.4, n=10).
doi:10.1371/journal.pone.0031188.g001
Figure 2. Alginate bead release kinetics of rLOX-PP. (A) Western
blot of known amounts of rLOX-PP ranging from 0.1 to 10 ng of rLOX-
PP; (B) Western blot of rLOX-PP-bead supernatants collected at different
intervals; (C) calculated cumulative release of rLOX-PP; (n=4;
*, p,0.001).
doi:10.1371/journal.pone.0031188.g002
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with apparent linear release between day 1 and day 7 (Figure 2B),
slowing after day 7 (Figure 2C). In total, 50% of rLOX-PP
encapsulated in alginate beads was released into buffer by day 14
(Figure 2C) with the remainder still bound to alginate. In vivo,
tightly bound LOX-PP would potentially be released because
alginate is progressively resorbed [26].
To determine the activity of rLOX-PP/alginate beads to
effectively inhibit breast cancer xenograft growth we first
established NF639 tumors as described in Materials and Methods.
Empty alginate beads or beads containing a total of 35 micro-
grams rLOX-PP were then implanted adjacent to the xenografts
through a small incision made on each of two sides of the tumor.
rLOX-PP/alginate beads significantly inhibited tumor growth
Figure 3. rLOX-PP incorporated in alginate beads inhibits NF639 xenograft growth in mice compared to empty beads. (A)
Subcutaneous 100 mm
3 xenografts of NF639 breast cancer cells were established in mice. rLOX-PP/alginate or empty beads were implanted on day
15 (arrow). Tumors were monitored by caliper measurements (n=10; *, p,0.05, ***, p,0.01). (B) The tumor growth rates were determined from
measurements made beginning on day 18 and were derived from linear regression analyses of the data; (C) tumor weights determined at sacrifice on
day 25 (n=10; *, p,0.05).
doi:10.1371/journal.pone.0031188.g003
Figure 4. Proliferation marker Ki-67 is decreased by rLOX-PP treatment. (A) Immunostaining with Ki-67 antibody or non-immune IgG
control tumors after (A) direct i.t. injection of rLOX-PP compared to PBS and (B) after implantation of empty and rLOX-PP alginate beads. Black arrows
mark some positive-stained cells; the white arrows point to an inset containing an enlarged image of a stained cell. (C) The corresponding
quantifications are shown (***, p,0.001; n=3). Scale bar=0.005 mm.
doi:10.1371/journal.pone.0031188.g004
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size in animals implanted with rLOX-PP were 7%, 36% and 38%
lower on days 18, 21, and 25, respectively, compared to control
mice. The tumor growth rate was determined by plotting tumor
volumes beginning on day 18 and revealed a rate of 110 mm
3/day
for control tumors (empty beads) compared to 42 mm
3/day for
the rLOX-PP treated tumors (rLOX-PP/alginate beads), demon-
strating a 61% reduction in growth rate after rLOX-PP bead
implantation adjacent to tumor xenografts (Figure 3B). The final
average tumor weight at sacrifice was 30% lower after rLOX-PP/
alginate bead implantation (Figure 3C). In summary, data indicate
that rLOX-PP/alginate bead implantation resulted in lower final
tumor volume by 38% on day 25, 30% lower final tumor weight,
and a 61% lower tumor growth. Taken together, findings show
that both i.t. injection of rLOX-PP and slow release formulations
of rLOX-PP effectively inhibit NF639 xenograft growth. In
addition, it is apparent that a lower amount of rLOX-PP
(35 micrograms) when administered in a slow release formulation
is more effective at inhibiting tumor growth than i.t. injection of a
higher total amount of rLOX-PP (a total of 50 micrograms:
10 micrograms per day as described above).
rLOX-PP inhibits tumor growth by reducing proliferation
and increasing apoptosis
In order to gain insights into mechanisms by which LOX-PP
inhibits tumor growth in vivo, we first evaluated relative
expression levels of Ki-67 by immunohistochemistry in harvested
tumors. Ki-67 is a marker for cell proliferation, and is expressed in
all phases of the cell cycle except G0, and is a predictive and
prognostic marker for breast cancer [27,28,29,30,31]. A higher
number of Ki-67 immunopositive cells were observed in sections
injected with PBS or implanted with empty beads compared to
rLOX-PP injection or rLOX-PP/alginate beads implantation, as
seen in representative sections (Figure 4A and 4B). The proportion
of Ki-67 immunopositive cells was reduced by both direct i.t.
injection of rLOX-PP and rLOX-PP/alginate beads compared to
their respective controls (Figure 4C; p,0.001). In addition, histone
H3 is phosphorylated specifically during mitosis and is also
frequently used as a proliferation marker in cancer. Both Ki-67
and phosphorylated histone H3 have been used for identification
of aggressive human breast and ovarian cancer and positively
correlate with the tumor grade [32,33]. Data in Figure 5A and 5B
suggest the presence of a reduced number of phospho-histone H3
stained cells in both direct i.t. injection of rLOX-PP and rLOX-
PP/alginate bead treated tumors compared to their respective
controls. The quantitation of phospho-histone H3 from tumor
tissue protein extracts by Western blotting showed an average
reduction of 45–50% in both i.t. injection of LOX-PP (Figure 5C;
p,0.05) and rLOX-PP/alginate beads (Figure 5D; p,0.05).
Thus, direct i.t. injection of rLOX-PP and rLOX-PP/alginate
beads each respectively reduced Ki-67 and phospho-histone H3 by
approximately 50% in this breast cancer xenograft model.
Apoptosis is induced by at least two different pathways: death
receptor (extrinsic) and mitochondrial (intrinsic) pathways. Both
Figure 5. Proliferation marker phosphorylated histone H3 is decreased by rLOX-PP treatment. (A) Immunostaining with phospho-
histone H3 antibody or nonimmune IgG control tumors after (A) direct i.t. injection of rLOX-PP (L) compared to PBS (P) and (B) after implantation of
empty (EB) and rLOX-PP (LB) alginate beads. Black arrows mark some positive-stained cells; the white arrows point to an inset containing an enlarged
image of a stained cell. Scale bars correspond to 0.005 mm for 4006and 0.002 mm for 10006. Arrows mark some positively stained cells. (C) Western
blot analyses of 17 kDa phospho- histone H3, 36 kDa beta-actin and the corresponding quantifications of protein extracts from tumors after (C) direct
i.t. injections of rLOX-PP compared to PBS and (D) after implantation of empty and rLOX-PP alginate beads (*, p,0.01; n=3).
doi:10.1371/journal.pone.0031188.g005
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immunohistochemistry. Representative micrographs (Figures 6A
and 6B) and quantitative scoring of all data (Figure 6C) suggest
that both i.t. injection and slow release of rLOX-PP increased the
number of cells staining for active cleaved caspase-3 in breast
cancer xenografts.
To determine more directly whether apoptosis and DNA
fragmentation were enhanced by rLOX-PP, we performed
TUNEL assays as indicated in Materials and Methods. TUNEL
positive cells (Figure 7A and B) were found to be significantly
increased to about 10% of cells in sections with rLOX-PP i.t.
injection or rLOX-PP/alginate beads, compared to about 2% for
controls (Figure 7C; p,0.0001). Taken together with activated
caspase 3 measurements shown in Figure 6, the data indicate that
rLOX-PP inhibits proliferation and stimulates apoptosis in breast
cancer xenografts.
We next investigated whether LOX-PP itself could be detected
in harvested tumors using a specific anti-LOX-PP antibody in
immunohistochemistry assays [34]. As seen in Figure 8, data
indicate that rLOX-PP is easily detected at elevated levels in
tumors from mice implanted with rLOX-PP alginate beads
compared to empty beads. By contrast, although the same trend
is observed in tumors derived from direct i.t. injection experi-
ments, the level of detectable rLOX-PP appears to be less than for
rLOX-PP/alginate.
We next evaluated a downstream target of Ras signaling to ask
whether the mechanism of rLOX-PP protein in vivo is likely to
occur by mechanisms that we have described in vitro and in
ectopic expression studies both in vitro and in vivo. Figure 9 shows
that Erk1/2 phosphorylation was inhibited by more than 70%
after rLOX-PP i.t. injections (Figure 9A) and rLOX-PP/alginate
slow release (Figure 9B) compared to respective controls. Thus,
data are consistent with findings that rLOX-PP protein functions
by inhibiting Ras signaling in a pre-clinical breast cancer xenograft
model.
Discussion
HereweshowforthefirsttimethatrLOX-PPproteininhibitspre-
existing tumor growth after direct i.t. injection or when applied in a
slow release formulation. Intratumoral injection studies have been
classically done in initial studies to evaluate the ability of proteins to
inhibit tumor growth. Direct i.t. injection of tumor necrosis factor-
alpha and interferons, or interferons alone, were shown to inhibit
xenograftgrowthinmice[35,36,37].Inhumanpatients,i.t.injection
of recombinant IL-2 induced tumor killing, tumor necrosis and
lymphocytic infiltration [38]. Thus, consistent with other pre-clinical
and clinicalstudies,itishereshownthatdirecti.t.injectionofrLOX-
PP inhibited the growth of a pre-existing breast cancer xenograft.
Interestingly, the slow release formulation appeared to be more
effective than i.t. injection of naked rLOX-PP in the inhibition of
NF639 xenograft growth. Although, LOX-PP has been shown to
have tumor suppressor properties, the effectiveness of rLOX-PP
protein to inhibit pre-existing tumor growth has not been previously
evaluated in vivo. Such studies are important in the evaluation of
therapeutic potential.
Alginate beads have been used previously for successful slow
release of recombinant proteins with a high isoelectric point
Figure 6. Apoptosis marker active caspase 3 is increased by rLOX-PP treatment. (A) Immunostaining of tumors with active caspase 3
antibody, or non-immune IgG control. (A) i.t. rLOX-PP- or PBS injected tumors, and (B) tumors treated with surgically implanted empty alginate beads
or rLOX-PP/alginate beads. Black arrows mark some positive-stained cells; the white arrows point to an inset containing an enlarged image of a
stained cell. Scale bar=0.005 mm for 4006and 0.002 mm for 10006; (C) the corresponding quantifications (***, p,0.001; n=3).
doi:10.1371/journal.pone.0031188.g006
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studies, alginate beads containing human mature allogenic
chondrocytes were found to be an effective treatment for cartilage
defects in the knee showing significant improvement within six
months which shows that alginate is safe and feasible for
application in vivo in patients [39]. Alginate formulations,
therefore, could have potential for use in pre-clinical human
studies, although other carriers such as polylactide/polyglycolide
polymers may be more widely used [40]. Encapsulated proteins in
alginate beads are released by diffusion from and degradation of
Figure 7. Apoptosis marker TUNEL is increased by rLOX-PP treatment. (A) TUNEL staining of tumors treated i.t. with rLOX-PP, or tumors
injected with negative control PBS; (B) tumors treated with surgically implanted empty alginate beads or rLOX-PP alginate beads. Black arrows mark
some positive-stained cells; the white arrows point to an inset containing an enlarged image of a stained cell. Scale bar=0.005 mm for 4006and
0.002 mm for 10006; (C) the corresponding quantifications (***, p,0.001; n=3). Arrows mark some positive-stained cells.
doi:10.1371/journal.pone.0031188.g007
Figure 8. rLOX-PP persists in treated tumors. Immunostaining of tumors after sacrifice with LOX-PP antibody or non-immune IgG control from
mice after (A) direct i.t. injection of rLOX-PP compared to PBS or (B) after implantation of empty or rLOX-PP-containing alginate beads. Scale
bars=0.005 mm. Arrows mark some positive-stained cells.
doi:10.1371/journal.pone.0031188.g008
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is significant in that it provides proof of principle that rLOX-PP is
effective in vivo, especially in a slow release formulation. At
sacrifice, it was apparent that most of the bead material had been
resorbed in all implanted mice, as expected. Only 1–2 beads out of
the twelve beads implanted per mouse could be found at sacrifice
(data not shown) suggesting that more than 80% of rLOX-PP was
released in vivo.
The single implantation of alginate incorporated rLOX-PP is
more efficient than five i.t. injections of rLOX-PP. The total
amount of rLOX-PP incorporated in alginate beads was
35 micrograms and resulted in a more significant reduction in
tumor xenograft volume, growth rate and tumor weight compared
to 50 micrograms rLOX-PP direct i.t. injections over five days.
Similarly, other studies have shown that alginate encapsulation of
recombinant proteins are highly active in vivo. For example,
similar to our data with rLOX-PP, in vivo subcutaneous
implantation of a single dose of alginate beads containing IL-
17R was more effective in reducing inflammation when compared
to multiple subcutaneous injections of this anti-inflammatory
protein [41]. FGF-2 plays an important role in tissue repair and
has a very short half-life when administered parenterally. Surgical
implantation of FGF-2 bound to heparin-Sepharose beads
encapsulated in calcium alginate microcapsules in an arterial
injury model was more efficient in delivering FGF-2 within the
arterial wall when compared to intravenous administration [18].
Thus, consistent with other studies, rLOX-PP inhibits tumor
xenograft by direct i.t. injection or implantation of alginate
encapsulated rLOX-PP, yet the latter shows a stronger effect with
an apparently increased persistence of rLOX-PP in tumors as seen
in Figure 6. Although there are many possibilities to improve the
current formulation of rLOX-PP for in vivo application, the
current formulation of alginate beads with encapsulated rLOX-PP
inhibited tumor growth rate by more than 61% and provides proof
of principle that rLOX-PP protein in some form has therapeutic
potential. It now becomes of considerable interest to determine the
pharmacokinetics, pharmacodynamics, and stability and effective-
ness of systemically applied naked rLOX-PP and of protected
formulations of rLOX-PP that would be acceptable for human
trials in order to develop rLOX-PP as an anti-cancer drug
candidate.
In order to investigate mechanisms of inhibition, we evaluated
effects of rLOX-PP on cell proliferation and apoptosis. rLOX-PP
inhibits cell proliferation determined by reduced expression of two
independent proliferation markers: Ki-67 and phospho-histone
H3. Ki-67 has been used to evaluate the responsiveness of
chemotherapeutics to breast cancer patients and evaluate the risk
of tumor incidence after treatments [42,43]. Ki-67 has diagnostic
importance in distinguishing between benign and malignant
tumors [44,45,46], and is a prognostic factor for clinical breast
cancer patients [47,48,49]. Phospho-histone H3 has been similarly
employed to evaluate tumor grade and aggressiveness [32,33].
Phospho-histone H3 is a prognostic proliferation marker in triple
negative invasive lymph node-negative breast cancer [50].
Data further show that rLOX-PP induces apoptosis in breast
cancer xenografts which was evaluated by activated caspase 3
immunostaining and TUNEL assays. Apoptosis is induced by
different pathways which converge at caspase 3 activation, a pro-
apoptotic marker [51]. Recently, it has been shown that rLOX-PP
sensitizes pancreatic and breast cancer cells to doxorubicin
induced apoptosis in vitro [12], but whether rLOX-PP alone
could induce apoptosis in breast cancer xenografts in vivo was not
known. The mechanism by which rLOX-PP induces apoptosis of
cancer cells in vivo in the absence of other chemotherapeutic
agents as seen in the present study requires further evaluations.
The NCR nu/nu mouse model employed in the present study is
T-cell deficient, but contains natural killer (NK) cells and B cells. It
is, therefore, possible to speculate that the increased apoptosis
observed in rLOX-PP treated tumors in vivo could be driven by
enhanced sensitivity to NK cell-derived TRAIL, or FasL
stimulated signaling [52,53]. A greater understanding of molecular
mechanisms of action of LOX-PP may permit the design of
combinatorial therapeutic approaches that would be more
effective than individual chemotherapeutic approaches. As noted,
it is of interest that rLOX-PP inhibits tumor growth in vivo
characterized by inhibition of cell proliferation and induction of
apoptosis, whereas in vitro rLOX-PP alone inhibits proliferation
but has not been seen to promote apoptosis [12].
Earlier in vitro studies done with ectopic rLOX-PP expression
in cancer cell lines indicate that LOX-PP inhibits Ras-mediated
activation of Erk1/2 by inhibiting FGF-2 to FGFR1 receptor
binding and activation, and by direct interaction with Hsp70 and
c-Raf [14,15,16]. The current study extends these observations to
rLOX-PP protein administered in vivo in which we show highly
significant inhibition of Erk1/2 phosphorylation. It is likely that
mechanisms of LOX-PP identified primarily in vitro are operative
in vivo, but further study of individual molecular interactions in
vivo with wild type and mutant forms of rLOX-PP will be required
to investigate the relationship between specific molecular interac-
tions and actual inhibition of tumor growth. The observation of
similarities in the magnitudes of rLOX-PP administration on
altering levels of both proliferation and apoptosis markers, whereas
tumor inhibition is more pronounced in the slow release model is
likely to be coincidental. Without more continuous assays of
changes in the expression of these markers throughout the entire
experimental period, it is difficult to comment further. Important-
ly, the current study establishes experimental systems by which a
variety of questions can now be addressed in vivo.
In conclusion, rLOX-PP protein is effective in inhibiting mouse
xenograft growth. The data show that alginate bound rLOX-PP is
more efficient in inhibiting breast cancer xenograft compared to
Figure 9. LOX-PP inhibits Ras effector Erk1/2 phosphorylation
in vivo. Western blot analysis of 42 and 44 kDa phospho-Erk, total
Erk1/2 and 36 kDa beta-actin from tumor extracts after (A) direct i.t.
injections of rLOX-PP (L) compared to PBS (P); (B) after implantation of
empty (EB) and rLOX-PP (LB) alginate beads; (C) the corresponding
quantifications are shown (*, p,0.05; n=3).
doi:10.1371/journal.pone.0031188.g009
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which rLOX-PP inhibits breast cancer xenograft growth will
enhance the ability to design potentially more effective combina-
tions of anti-cancer regimens.
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